Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06145100
Other study ID # CVID-pHT
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date November 1, 2023
Est. completion date December 31, 2025

Study information

Verified date November 2023
Source University Hospital Freiburg
Contact Dominik Bettinger, MD
Phone +49761270-36870
Email dominik.bettinger@uniklinik-freiburg.de
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Patients with CVID will be offered to participate in this observational trial during the routine annual visit in the outpatient clinic at the Center of chronic Immunodeficiency (CCI) of the University Medical Center Freiburg, Germany. Clinical and laboratory data at the time of presentation will be assessed. Additionally, parameters of abdominal ultrasound, duplex sonography of the liver and spleen, and liver and spleen stiffness at the time of presentation will be evaluated. If applicable, clinical and/or interventional parameters indicating clinically significant portal hypertension (i.e. presence of varices or portal-hypertensive gastropathy in esophago-gastroduodenoscopy, presence of ascites) within 12 months prior and after the index visit will be assessed. During the visit, serum/plasma samples and peripheral blood mononuclear cells (PBMC) are collected and stored in an associated biobank.


Description:

Patients with CVID can be included in the study. The study cohort will consist of three subgroups: 1) Patients with CVID and autoimmunity, but no liver involvement. 2) Patients with CVID and liver involvement, defined by elevated liver enzymes, abnormal ultrasound and/or abnormal liver biopsy, but no signs of clinically significant portal hypertension and 3) Patients with CVID and clinically significant non-cirrhotic portal hypertension. Further, patients with CVID and diagnosed non-cirrhotic portal hypertension between 01/01/2004 and the start of the prospective part of this study (01/01/2023) will be included retrospectively in this study. Patients will be recruited during the routine annual visit in the outpatient clinic at the Center of chronic Immunodeficiency (CCI) of the University Medical Center Freiburg, Germany. During the visit a standard ultrasound protocol, including size and morphology of liver and spleen, duplex-sonography of the liver, and measurement of liver and spleen stiffness via transient elastography will be performed as a part of the routine clinical diagnostic. Results from endoscopy or other interventions (esophago-gastroduodenoscopy, invasive measurement of hepatic venous-portal pressure gradient, or TIPS implantation, if applicable) within 12 months prior and after the index visit will be assessed. All non-invasive and invasive interventions will be conducted solely based on clinical decisions made independently from the study inclusion as the study is designed as an observational study. Detailed patient characteristics, epidemiologic, clinical, imaging and laboratory parameters will be assessed and included in an electronic database. Apart from these data, patients will be asked to participate in biobank sampling including serum/plasma and peripheral blood mononuclear cells (PBMC) samples from the peripheral veins. All patients recruited in this study will be followed-up for at least 12 months. Outcome parameters include parameters from abdominal ultrasound, duplex-sonography and stiffness of liver and spleen, presence or development of clinically significant portal hypertension and non-invasive fibrosis scores based on laboratory and ultrasound parameters.


Recruitment information / eligibility

Status Recruiting
Enrollment 250
Est. completion date December 31, 2025
Est. primary completion date December 31, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Patients with CVID Exclusion Criteria: - no written informed consent - concomitant chronic liver disease (viral hepatitis, alcoholic liver disease, steatitic liver disease, hemochromatosis, primary biliary cholangitis, primary sclerosis cholangitis, M. Wilson, alpha-1-antitrypsin deficiency)

Study Design


Related Conditions & MeSH terms


Intervention

Diagnostic Test:
Ultrasound including color doppler ultrasound
Patients with CVID receive color doppler ultrasound of the liver including assessment of portal vein diameter, portal vein flow velocity, hepatic vein diameter and assessment of arterial perfusion. Further liver and spleen stiffness measurement by transient elastography is performed.

Locations

Country Name City State
Germany University Medical Center Freiburg, Department of Medicine II Freiburg

Sponsors (1)

Lead Sponsor Collaborator
University Hospital Freiburg

Country where clinical trial is conducted

Germany, 

Outcome

Type Measure Description Time frame Safety issue
Primary Differences in liver stiffness between CVID patients with and without liver involvement and with clinically significant portal hypertension. Liver stiffness will be assessed by transient elastography. Study inclusion, after 12 months
Primary Differences in spleen stiffness between CVID patients with and without liver involvement and with clinically significant portal hypertension. Spleen stiffness will be assessed by transient elastography. Study inclusion, after 12 months
Secondary Differences in portal vein diameter between CVID patients with and without liver involvement and with clinically significant portal hypertension. Portal vein diameter will be assessed by color doppler ultrasound Study inclusion, after 12 months
Secondary Differences in portal vein flow velocity between CVID patients with and without liver involvement and with clinically significant portal hypertension. Portal vein flow velocity will be assessed by color doppler ultrasound Study inclusion, after 12 months
Secondary Differences in alanine aminotransfersases (ALT) between CVID patients with and without liver involvement and with clinically significant portal hypertension. ALT is assessed during routine clinical practice Study inclusion, after 12 months
Secondary Differences in aspartat aminotransfersases (AST) between CVID patients with and without liver involvement and with clinically significant portal hypertension. AST is assessed during routine clinical practice Study inclusion, after 12 months
Secondary Differences in liver function tests (bilirubin, albumin, INR) between CVID patients with and without liver involvement and with clinically significant portal hypertension. Liver function liver function tests (bilirubin, albumin, INR) are assessed during routine clinical practice Study inclusion, after 12 months
Secondary Differences in platelets between CVID patients with and without liver involvement and with clinically significant portal hypertension. Platelets are assessed during routine clinical practice Study inclusion, after 12 months
See also
  Status Clinical Trial Phase
Recruiting NCT03663933 - Allogeneic Hematopoietic Cell Transplantation for Disorders of T-cell Proliferation and/or Dysregulation Phase 2
Recruiting NCT01652092 - Allogeneic Hematopoietic Stem Cell Transplant for Patients With Primary Immune Deficiencies N/A
Recruiting NCT05321407 - COVID-19 Vaccine Responses in PIDD Subjects
Recruiting NCT04339777 - Allogeneic Hematopoietic Stem Cell Transplant for Patients With Inborn Errors of Immunity Phase 2
Completed NCT00542997 - Study of Subcutaneous Immune Globulin in Patients Requiring IgG Replacement Therapy Phase 3
Completed NCT00168025 - Efficacy and Safety of Intravenous Immunoglobulin IgPro10 in Patients With Primary Immunodeficiencies (PID) Phase 3
Completed NCT00168012 - Efficacy and Safety of Intravenous Immunoglobulin IVIG-F10 in Patients With Primary Immunodeficiencies (PID) Phase 3
Completed NCT00004695 - Randomized Study of Polyethylene-Glycol-Conjugated Interleukin 2 in Patients With Common Variable Immunodeficiency N/A
Completed NCT01196702 - Lymphocyte Immunophenotyping in Common Variable Immunodeficiency
Recruiting NCT06355323 - Bronchiectasis Prevalence in Patients With Primary Humoral Immunodefiency in Champagne-Ardenne Region, France N/A
Completed NCT00322556 - Safety and Efficacy of Intravenous Immunoglobulin IgPro10 in Patients With Primary Immunodeficiencies (PID) Phase 3
Recruiting NCT02579967 - Pilot Trial of Allogeneic Blood or Marrow Transplantation for Primary Immunodeficiencies Phase 2
Completed NCT01289847 - A Study to Find Out How Safe and Effective Gammaplex® is in Young People With Primary Immunodeficiency Phase 4
Completed NCT00520494 - Efficacy and Safety of Vivaglobin® in Previously Untreated Patients With Primary Immunodeficiency Phase 4
Terminated NCT00006054 - Allogeneic Bone Marrow Transplantation in Patients With Primary Immunodeficiencies N/A
Completed NCT03211689 - The Impact of Exercise on Stress, Fatigue, and Quality of Life in Individuals With Primary Immunodeficiency Disease N/A
Terminated NCT01489618 - "Prime Boost" Vaccination Strategy Combining Conjugated Anti- Pneumococcal Vaccine (s0) and Polysaccharide Anti- Pneumococcal Vaccine (s4) Compared to Polysaccharide Anti- Pneumococcal Vaccine Alone (s4) In Patients With Common Variable Immunodeficiency Phase 2
Completed NCT03513328 - Conditioning Regimen for Allogeneic Hematopoietic Stem-Cell Transplantation Phase 1/Phase 2
Completed NCT03188419 - Breadth of Donor Options for People With Inherited Diseases Requiring Allogeneic Hematopoietic Stem Cell Transplant in the Era of Alternative Donor Transplants Using Post-Transplantation Cyclophosphamide
Not yet recruiting NCT05481554 - Composition and Function of Gut Microbiota in Porto-sinusoidal Vascular Disease Associated With Variable Common Immunodeficiency